KHPG(SZ:002773)2022-11-22 02:54Group 1: Clinical Trials and Product Development - The clinical trial for Kangbaxipu (康柏西普) faced failures due to various factors, and the company is currently analyzing the data to understand the reasons [2][3][4] - Kangbaxipu has been on the market for 7 years, with cumulative sales exceeding 1 billion CNY for two consecutive years, indicating strong market performance [4][5] - The company is advancing several projects, including KH805 and KH806 for diabetes, which are in preclinical research stages [5][8] Group 2: Financial Performance and Investor Relations - The company's stock price is influenced by its performance and growth potential, with ongoing efforts to meet annual growth targets [3][4] - Kangbaxipu's sales in the first four months of 2021 showed continued growth, reinforcing confidence in achieving financial targets for the year [4][5] - The company has maintained a research and development investment of around 20% in recent years, although this may fluctuate due to the impact of halted overseas trials [6][7] Group 3: Market Strategy and Future Plans - The company does not currently plan to enter the medical aesthetics market, focusing instead on its core pharmaceutical business [7][8] - Future product lines include innovative drugs in various therapeutic areas, with a commitment to developing first-in-class or best-in-class products [8][9] - The company is exploring opportunities in synthetic biology and gene therapy, with several projects progressing well [7][8]